MX2013011996A - Metodos para regular la expresion de genes de sirtuina. - Google Patents

Metodos para regular la expresion de genes de sirtuina.

Info

Publication number
MX2013011996A
MX2013011996A MX2013011996A MX2013011996A MX2013011996A MX 2013011996 A MX2013011996 A MX 2013011996A MX 2013011996 A MX2013011996 A MX 2013011996A MX 2013011996 A MX2013011996 A MX 2013011996A MX 2013011996 A MX2013011996 A MX 2013011996A
Authority
MX
Mexico
Prior art keywords
gene expression
methods
sirtuin gene
regulating sirtuin
regulating
Prior art date
Application number
MX2013011996A
Other languages
English (en)
Inventor
Yuanlong Pan
Rondo Paul Middleton
Original Assignee
Nestec Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nestec Sa filed Critical Nestec Sa
Publication of MX2013011996A publication Critical patent/MX2013011996A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/105—Plant extracts, their artificial duplicates or their derivatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/06—Free radical scavengers or antioxidants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Abstract

La invención proporciona métodos útiles para regular expresión de genes de sirtuina, imitar restricción calórica, prevenir y tratar enfermedad de Alzheimer, incrementar longevidad y retrasar envejecimiento en un animal. Los métodos comprenden administrar una o más isoflavonas a los animales, de preferencia en cantidades de alrededor de 0.001 a aproximadamente 10 g/kg/día.
MX2013011996A 2011-04-15 2012-03-26 Metodos para regular la expresion de genes de sirtuina. MX2013011996A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201161517228P 2011-04-15 2011-04-15
PCT/US2012/030509 WO2012141876A1 (en) 2011-04-15 2012-03-26 Methods for regulating sirtuin gene expression

Publications (1)

Publication Number Publication Date
MX2013011996A true MX2013011996A (es) 2013-11-01

Family

ID=47009640

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2013011996A MX2013011996A (es) 2011-04-15 2012-03-26 Metodos para regular la expresion de genes de sirtuina.

Country Status (11)

Country Link
US (1) US20140039047A1 (es)
EP (2) EP2696692A4 (es)
JP (1) JP6140682B2 (es)
CN (1) CN103596563A (es)
AU (1) AU2012243210B2 (es)
BR (1) BR112013026447A2 (es)
CA (1) CA2832234A1 (es)
MX (1) MX2013011996A (es)
RU (1) RU2603749C2 (es)
WO (1) WO2012141876A1 (es)
ZA (1) ZA201308585B (es)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102016078B1 (ko) 2012-11-30 2019-08-30 (주)아모레퍼시픽 심장 질환 예방 또는 치료용 조성물
AU2015362283B2 (en) * 2014-12-09 2020-07-30 Amorepacific Corporation Composition for activating longevity gene
TWI556818B (zh) * 2015-08-07 2016-11-11 長庚大學 哺乳類sirt1的活化劑
WO2021068242A1 (en) * 2019-10-12 2021-04-15 Shenzhen University An agent that enables sirt7 gene expression and the use thereof
CN111450098A (zh) * 2020-04-20 2020-07-28 中国科学院动物研究所 拉米夫定在延缓衰老中的应用以及制备用于筛选延缓衰老药物的细胞模型
KR20230009417A (ko) * 2020-05-11 2023-01-17 산토리 홀딩스 가부시키가이샤 니코틴아미드 아데닌 디뉴클레오티드(nad) 농도상승제
JPWO2022050308A1 (es) * 2020-09-04 2022-03-10
CN115429810B (zh) * 2021-06-03 2024-03-08 苏州禾研生物技术有限公司 异黄酮类化合物在制备预防或治疗酒精性肝损伤或解酒保肝的药物中的用途
WO2023150072A1 (en) 2022-02-01 2023-08-10 Sinclair David A Compositions and methods for the preservation of plant matter

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5733926A (en) * 1996-12-13 1998-03-31 Gorbach; Sherwood L. Isoflavonoids for treatment and prevention of alzheimer dementia and reduced cognitive functions
US5952033A (en) 1996-12-24 1999-09-14 Nestec S.A. Gelatinized cereal product containing oligosaccharide and processes of preparing and using same
DE29724816U1 (de) 1997-01-09 2004-07-22 Société des Produits Nestlé S.A. Probiotik enthaltendes Getreideprodukt
AU770075B2 (en) * 1999-02-24 2004-02-12 Mars, Incorporated Dietary compositions and methods
EP1213970B1 (en) 1999-09-07 2008-06-11 Societe Des Produits Nestle S.A. Method for improving the skin and coat of pets
EP1143806B1 (en) 1999-09-22 2006-04-19 Societe Des Produits Nestle S.A. Method for increasing pet activity
WO2001090311A1 (en) 2000-05-25 2001-11-29 Societe Des Produits Nestle S.A. Novel probiotics for pet food applications
AU6231501A (en) 2000-05-26 2001-12-11 Nestle Sa Foodstuff for pets or other animals
GB0027761D0 (en) 2000-11-14 2000-12-27 Nestle Sa Nutritional composition for an immune condition
EP1344458A1 (en) 2002-03-12 2003-09-17 Société des Produits Nestlé S.A. Probiotic delivery system
WO2004039327A2 (en) * 2002-10-29 2004-05-13 Colorado State University Research Foundation Use of equol for treating androgen mediated diseases
CA2559974C (en) * 2004-03-17 2012-08-14 Nestec S.A. Compositions and methods for reducing or preventing obesity
WO2006001982A2 (en) * 2004-06-04 2006-01-05 Washington University Methods and compositions for treating neuropathies
JP2008527002A (ja) * 2005-01-13 2008-07-24 サートリス ファーマシューティカルズ， インコーポレイテッド 神経変性障害および血液凝固障害を予防および処置するための新規組成物
AU2006206274A1 (en) * 2005-01-20 2006-07-27 Sirtris Pharmaceuticals, Inc. Use of sirtuin-activating compounds for treating flushing and drug induced weight gain
US20070149466A1 (en) * 2005-07-07 2007-06-28 Michael Milburn Methods and related compositions for treating or preventing obesity, insulin resistance disorders, and mitochondrial-associated disorders
EP1956923A1 (en) * 2005-11-02 2008-08-20 Nestec S.A. Isoflavone compositions for reducing accumulation of body fat in male mammals, and methods for their use
HUE032901T2 (hu) * 2006-02-28 2017-11-28 Nestec Sa Készítmények és eljárások csontnövekedés elõidézésére és csontvesztés gátlására
US20080108696A1 (en) * 2006-08-02 2008-05-08 Brinton Roberta D Phytoestrogenic Formulations for Alleviation or Prevention of Neurodegenerative Diseases
CN101200459A (zh) * 2006-12-11 2008-06-18 南京莱尔生物化工有限公司 一种雌马酚的合成方法

Also Published As

Publication number Publication date
RU2603749C2 (ru) 2016-11-27
ZA201308585B (en) 2015-06-24
CN103596563A (zh) 2014-02-19
EP2696692A1 (en) 2014-02-19
AU2012243210A1 (en) 2013-10-24
BR112013026447A2 (pt) 2016-10-18
RU2013150828A (ru) 2015-05-20
JP6140682B2 (ja) 2017-05-31
EP2898923A2 (en) 2015-07-29
US20140039047A1 (en) 2014-02-06
EP2696692A4 (en) 2014-10-01
WO2012141876A1 (en) 2012-10-18
CA2832234A1 (en) 2012-10-18
AU2012243210B2 (en) 2016-07-14
EP2898923A3 (en) 2015-10-07
JP2014516359A (ja) 2014-07-10

Similar Documents

Publication Publication Date Title
MX2013011996A (es) Metodos para regular la expresion de genes de sirtuina.
AU2018236800B2 (en) DNA-PK inhibitors
TN2012000081A1 (en) Compounds and compositions as protein kinase inhibitors
PH12014502280A1 (en) Indole and indazole compounds that activate ampk
UA109878C2 (uk) Похідні ізохінолінону, фармацевтична композиція на їх основі (варіанти) та спосіб лікування захворювань (варіанти)
MX359327B (es) Composiciones y sus usos para tratar y prevenir la enfermedad de huntington.
SG10201808903UA (en) Compositions for modulating c9orf72 expression
TN2013000348A1 (en) Compounds and compositions as trk inhibitors
MX2013010343A (es) Composicion y metodos para el transplante de microbiota de colon.
TN2010000122A1 (en) Compounds and compositions as modulators of gpr119 activity
DK2459216T3 (da) Immunogene sammensætninger omfattende tlr-aktivitetsmodulatorer
MD4531C1 (ro) Derivaţi ai benzimidazolonei în calitate de inhibitori ai bromodomeniului
MX2009009491A (es) Compuestos y composiciones como moduladores de la actividad del gpr119.
MY165728A (en) Selective glycosidase inhibitors and uses thereof
MX362550B (es) Inhibidores ciclicos de glutaminasa.
SG10201808063PA (en) Compositions for modulating ataxin 2 expression
PH12018502580A1 (en) Formulations for paddy rice fields
GEP20186864B (en) Diacylglycerol acyltransferase 2 inhibitors for use in the treatment of metabolic and related disorders
IN2012DN02624A (es)
MX2012004078A (es) Compuestos y composiciones como moduladores de la actividad de gpr119.
MX342257B (es) Derivados y análogos de oxaspiro [2.5] octano.
IN2015DN01151A (es)
MX2012001134A (es) Composiciones y metodos para inhibicion de la via jak.
EA201691020A1 (ru) Способы лечения и предотвращения вызываемой аллогенными антителами хронической болезни "трансплантат против хозяина"
GEP20166489B (en) 1h-indazole-3-carboxamide compounds as glycogen synthase kinase 3 beta inhibitors